Mylan, Novo Nordisk
Mylan settles patent litigation with Novo Nordisk over generic Ozempic in United States
“Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement of the US patent litigation related to generic Ozempic (Semaglutide),” NATCO said in the filing. The terms of the settlement are confidential, it added.
Danish drugmaker Novo Nordisk will invest 864 million reais ($158.2 million) to revamp a plant in Brazil responsible for ...
9d
In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D ...
Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for ...
4don MSN
The company is expected to present critical results from a trial of its CagriSema weight-loss injection in the fourth quarter ...
The general mood among these heavyweight investors is divided, with 45% leaning bullish and 50% bearish. Among these notable ...
Danish drugmaker Novo Nordisk said on Tuesday it has mitigation plans in place to minimize or prevent any disruption to its ...
Novo Nordisk (NVO) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee on ...
Novo Nordisk is investing $158 million to revamp a plant in Brazil responsible for a quarter of the Danish company’s global ...
In terms of liquidity and interest, the mean open interest for Novo Nordisk options trades today is 703.94 with a total ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback